InVivid (IVVD) Q4 2025: Pemgarda Revenue Climbs 31% QoQ, Pivotal VYD2311 Data in Sight

2026-03-05 | By EarningsIQ Research

InVivid accelerated commercial traction in Q4 with Pemgarda, while its next-gen VYD2311 antibody program reached pivotal trial enrollment, setting up a potential inflection in COVID prophylaxis strategy. Strategic pipeline expansion into RSV and measles underscores a deliberate push to broaden the company’s infectious disease franchise. Investors now look to Declaration study data mid-2026 for validation of InVivid’s vaccine-alternative positioning and commercial scale-up potential.

Summary

• Commercial Expansion Drives Platform Validation: Pemgarda growth and repeat utilization support a durable base for broader monoclonal antibody adoption.
• Pipeline Execution Reaches Key Milestone: VYD2311 pivotal trial enrollment and regulatory engagement set up a major clinical catalyst in mid-2026.
• Broader Infectious Disease Ambitions Materialize: RSV and measles programs signal a multi-virus, pediatric-inclusive strategy beyond COVID.

Business Overview

InVivid develops and commercializes monoclonal antibody therapies targeting infectious diseases, with a current focus on COVID-19, RSV (respiratory syncytial virus), and measles. The company generates revenue primarily through the sale of Pemgarda, its COVID-19 prophylactic antibody, and is advancing next-generation candidates like VYD2311 and pipeline assets for broader viral prevention. Key segments include commercialized COVID antibodies, late-stage clinical programs, and early-stage research for pediatric and immunocompromised populations.

Performance Analysis

Pemgarda, InVivid’s lead COVID-19 antibody, delivered a 31% sequential revenue increase and 25% year-over-year growth in Q4, reflecting deepening adoption across specialty sites and a 77% reorder rate. Full-year net revenues reached $53.4 million, underpinned by expanded GPO (group purchasing organization) contracts and growing clinical guideline inclusion. The company ended 2025 with $226.7 million in cash, after raising over $200 million in the latter half of the year, providing a runway through pivotal VYD2311 data and potentially further, contingent on continued commercial momentum.

Operational discipline and robust cash reserves position InVivid to sustain pipeline execution and commercial scaling even as it invests in new indications. The company’s ability to drive repeat utilization and expand its specialty site footprint signals increasing physician confidence and a solidifying market for monoclonal antibody prophylaxis, especially among immunocompromised patients. Notably, the business model is evolving from a single-product focus to a multi-pathogen, multi-population platform—an approach that could insulate against single-market volatility but introduces clinical and regulatory complexity.

• Commercial Uptake Accelerates: High Pemgarda reorder rates and expanded GPO reach validate demand and operational execution.
• Cash Position Enables Pipeline Agility: Over $226 million in cash supports ongoing trials and future launches without near-term financing risk.
• Pipeline Diversification Emerges: RSV and measles antibody programs advance, broadening the addressable market and leveraging core antibody capabilities.

InVivid’s trajectory now hinges on the Declaration trial for VYD2311, which, if successful, could transform the company’s revenue base and strategic relevance in infectious disease prevention.

Executive Commentary

Strategic Positioning

1. COVID Prophylaxis as a Platform, Not a Product

InVivid’s strategy centers on establishing monoclonal antibodies as a durable alternative to vaccination, particularly for vulnerable populations. The company leverages clinical trial rigor—three placebo-controlled studies in five years—to differentiate its approach from mRNA vaccines, emphasizing safety, adaptability to viral evolution, and convenience (e.g., intramuscular VYD2311). This foundational bet is reinforced by increasing inclusion in clinical guidelines and specialty societies, supporting a category-creation narrative.

2. Pipeline Expansion and Pediatric Focus

RSV and measles programs signal a deliberate pivot toward multi-virus, pediatric, and immunocompromised indications. InVivid’s RSV antibody is positioned as “potentially best-in-class,” designed to address viral drift and known liabilities in incumbent therapies. The measles antibody is being developed for outbreak response, bridge-to-vaccine use, and potential vaccine enhancement, reflecting a nuanced understanding of immune system development in infants and unmet needs flagged by clinicians.

3. Regulatory and Clinical Trial Execution

The Declaration study for VYD2311 reached target enrollment ahead of schedule, with protocol flexibility to upsize if community infection rates require more statistical power. The Independent Data Monitoring Committee’s favorable safety recommendations (e.g., expanded eligibility, reduced safety visits) de-risk the program and could accelerate timelines. The company’s focus on “attack rate” optimization and site selection reflects a sophisticated approach to trial powering in a post-pandemic environment.

4. Commercial Infrastructure and Market Education

InVivid has built a robust commercial foundation for Pemgarda, expanding its GPO network to over 15,000 sites and driving high repeat utilization across hematology, oncology, rheumatology, and other specialties. Educational partnerships and high-profile advocates (e.g., Lindsey Vonn) are being leveraged to shift the treatment paradigm toward proactive antibody prophylaxis, reinforcing the company’s thought-leadership position.

Key Considerations

This quarter marked a transition from single-product execution to platform-building, with the company balancing near-term commercial gains against longer-term pipeline bets. Investors should weigh the durability of Pemgarda demand, the binary risk of Declaration trial outcomes, and the operational demands of multi-indication expansion.

Key Considerations:

• Trial Powering and Timeline Management: Declaration’s upsizing algorithm and rapid recruitment reflect strong execution, but event rate variability could impact data timing.
• Addressable Market Expansion: Pediatric and outbreak-driven use cases for RSV and measles antibodies could unlock new revenue streams, contingent on regulatory and clinical success.
• Guideline Inclusion and Specialty Adoption: Growing recognition in NCCN and other guidelines boosts credibility and supports commercial scaling.
• Cash Burn Versus Pipeline Acceleration: Ample cash enables aggressive development, but future capital needs will resurface if pipeline programs move into larger trials or commercial launches.

Risks

Declaration trial outcomes represent a binary risk for both commercial scale and platform validation. Event rate unpredictability, regulatory shifts, and competitive advances in monoclonal antibodies or vaccines could disrupt execution. Expansion into RSV and measles brings new clinical, regulatory, and market risks, especially as the company moves beyond its core COVID focus. Pipeline breadth could stretch operational resources, and payer adoption for broader prophylaxis indications remains unproven.

Forward Outlook

For Q1 2026, InVivid guided to:

• Continued Pemgarda revenue growth and account expansion
• Declaration trial progress update, including potential resizing decision in April based on event rates

For full-year 2026, management maintained guidance for:

• Pivotal VYD2311 data readout by mid-year (2Q or 3Q 2026)

Management emphasized that Declaration trial upsizing, if triggered, is not expected to meaningfully delay overall timelines, and that cash reserves are sufficient to support operations through key catalysts. Ongoing pipeline updates for RSV and measles are expected in the first half of 2026.

• Mid-year Declaration data remains the primary near-term milestone
• Pipeline updates and commercial scaling will shape investor sentiment

Takeaways

InVivid’s Q4 performance cements its monoclonal antibody platform as a credible alternative to traditional vaccination, with commercial execution and pipeline breadth setting the stage for a pivotal year ahead.

• Pemgarda adoption validates monoclonal antibodies for vulnerable populations, supporting the company’s broader platform ambitions.
• VYD2311 pivotal trial progress is the defining catalyst, with upside in multi-pathogen pipeline expansion if clinical and regulatory execution continues apace.
• Investors should monitor Declaration data, pipeline updates, and commercial scaling as key drivers of valuation and strategic relevance in 2026.

Conclusion

InVivid enters 2026 with commercial momentum, a de-risked cash position, and a potentially transformative clinical catalyst in VYD2311. The company’s pivot to a multi-virus, pediatric-inclusive strategy raises both opportunity and execution risk, but clear progress this quarter positions it as a platform contender in infectious disease prophylaxis.

Industry Read-Through

InVivid’s progress highlights growing clinical and commercial acceptance of monoclonal antibodies as a platform for infectious disease prevention, especially for populations underserved by vaccines. The company’s success in driving specialty adoption and guideline inclusion signals a shift in market dynamics that could impact both established vaccine players and emerging antibody competitors. RSV and measles pipeline moves underscore a broader industry trend toward passive immunization, with implications for pediatric and outbreak management strategies across the sector. Competitors in the antibody and vaccine space will need to address viral evolution, safety, and convenience to remain relevant as the prophylaxis paradigm evolves.

IVVD Healthcare Biotechnology Infectious Disease Monoclonal Antibodies Pediatrics Pipeline COVID-19